Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway

Acta Pharmacologica Sinica

Volumn 33, Issue 10, 2012, Pages 1277-1284

  Hou, Jian Ming ^a   Xue, Ying ^a   Lin, Qing Ming ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

bone; bone mineral density; bone turnover; lactoferrin; OPG RANKL RANK pathway

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 TELOPEPTIDE; ESTRADIOL; LACTOFERRIN; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE METABOLISM; CONTROLLED STUDY; FEMALE; FEMUR; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OVARIECTOMY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; THICKNESS; TRABECULAR BONE; UTERUS WEIGHT;

ANALYSIS OF VARIANCE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR; LACTOFERRIN; LUMBAR VERTEBRAE; METABOLIC NETWORKS AND PATHWAYS; ORGAN SIZE; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; X-RAY MICROTOMOGRAPHY;

EID: 84867203022     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.83     Document Type: Article

References (30)

1. Garnero P, Delmas PD, Bilezikian JP. Evaluation of risk for osteoporosis fractures. Principles of Bone Biology 2002; 1291-301.
2. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin-a novel bone growth factor. Clin Med Res 2005; 5: 93-101.
3. Omi N, Ezawa I. The effect of ovariectomy on bone metabolism in rats. Bone 1995; 17: 163S-168S.
4. Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, Spik G, et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984; 145: 659-76.
5. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995; 15: 93-110.
6. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005; 62: 2540-8.
7. Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T, Iwatsuki K. Twenty-?ve years of research on bovine lactoferrin applications. Biochimie 2009; 91: 52-7.
8. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 2004; 145: 4366-74.
9. Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 2004; 18: 2268-78.
10. Grey A, Zhu Q, Watson M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol 2006; 251: 96-102.
11. Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A, Offord E. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 2002; 296: 261-6.
12. Takayama Y, Mizumachi K. Effect of lactoferrin-embedded collagen membrane on osteogenic differentiation of human osteoblast-like cells. J Biosci Bioeng 2009; 107: 191-5.
13. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin: a novel bone growth factor. Clin Med Res 2005; 3: 93-101.
14. Guo HY, Jiang L, Ibrahim SA, Zhang L, Zhang H, Zhang M, et al. Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 2009; 139: 958-64.
15. Bharadwaj S, Naidu AG, Betageri GV, Prasadarao NV, Naidu AS. Milk ribonuclease-enriched-lactoferrin induces positive effects on bone turnovermarkers in postmenopausal women. Osteoporos Int 2009; 20: 1603-11.
16. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-42.
17. Mitchner NA, Harris ST. Current and emerging therapies for osteoporosis. J Fam Pract 2009; 58: S45-9.
18. Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, et al. Defective bone remodelling in osteoprotegerin-decien mice. J Electron Microsc (Tokyo) 2003; 52: 503-13.
19. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412-24.
20. Manolagos SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-11.
21. Blais A, Malet A, Mikogami T, Martin-Rouas C, Tomé D. Oral bovine lactoferrin improves bone status of ovariectomized mice. Am J Physiol Endocrinol Metab 2009; 296: E1281-8.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
23. Melton LJ 3rd, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12: 1083-91.
24. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 2005; 75: 213-25.
25. Marie PJ. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008; 473: 98-105.
26. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
27. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
28. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
29. Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol 2007; 143: 31-48.
30. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, et al. Enhanced t-cell expression of rank ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-63.